The halt will remain in place until Monday 6th November 2017.
() remains focused on repurposing pentosan polysulfate sodium (PPS), an FDA-approved drug that has a long track record of safely treating inflammation.
Paradigm is repurposing PPS for a number of applications with a focus on treatment of orthopaedic and viral arthritic indications.
Drug repurposing comes at a lower cost, minimises risk and has accelerated development timelines.
The company is currently completing a capital raising, and the ASX has granted a trading halt to finalise.
The halt will remain in place until the opening of trade on Monday 6th November 2017, or earlier if an announcement is made to the market.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...
FOR OUR FULL DISCLAIMER CLICK HERE